Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection.

Ulz P, Perakis S, Zhou Q, Moser T, Belic J, Lazzeri I, Wölfler A, Zebisch A, Gerger A, Pristauz G, Petru E, White B, Roberts CES, John JS, Schimek MG, Geigl JB, Bauernhofer T, Sill H, Bock C, Heitzer E, Speicher MR.

Nat Commun. 2019 Oct 11;10(1):4666. doi: 10.1038/s41467-019-12714-4.

2.

The role of germline mutation profiling in the selection of related donors for haematopoietic stem cell transplantation.

Zebisch A, Winter G, Kashofer K, Hatzl S, Uhl B, Wurm S, Wölfler A, Greinix HT, Hoefler G, Sill H.

Bone Marrow Transplant. 2019 Sep 25. doi: 10.1038/s41409-019-0691-1. [Epub ahead of print] No abstract available.

PMID:
31554930
3.

The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML) : A representative and useful real-life data source for further biomedical research.

Geissler K, Jäger E, Barna A, Gurbisz M, Marschon R, Graf T, Graf E, Borjan B, Jilch R, Geissler C, Hoermann G, Esterbauer H, Schwarzinger I, Nösslinger T, Pfeilstöcker M, Tüchler H, Reisner R, Sliwa T, Keil F, Bettelheim P, Machherndl-Spandl S, Doleschal B, Zach O, Weltermann A, Heibl S, Thaler J, Zebisch A, Sill H, Stauder R, Webersinke G, Petzer A, Kusec R, Ulsperger E, Schneeweiss B, Berger J, Öhler L, Germing U, Sperr WR, Knöbl P, Jäger U, Valent P.

Wien Klin Wochenschr. 2019 Sep;131(17-18):410-418. doi: 10.1007/s00508-019-1526-1. Epub 2019 Jul 18.

4.

Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis.

Caraffini V, Geiger O, Rosenberger A, Hatzl S, Perfler B, Berg JL, Lim C, Strobl H, Kashofer K, Schauer S, Beham-Schmid C, Hoefler G, Geissler K, Quehenberger F, Kolch W, Athineos D, Blyth K, Wölfler A, Sill H, Zebisch A.

Haematologica. 2019 May 16. pii: haematol.2018.209650. doi: 10.3324/haematol.2018.209650. [Epub ahead of print]

5.

Detection of AML-specific TP53 mutations in bone marrow-derived mesenchymal stromal cells cultured under hypoxia conditions.

Müller M, Graf R, Kashofer K, Macher S, Wölfler A, Zebisch A, Hrzenjak A, Heitzer E, Sill H.

Ann Hematol. 2019 Aug;98(8):2019-2020. doi: 10.1007/s00277-019-03680-4. Epub 2019 Apr 2. No abstract available.

6.

High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML.

Daga S, Rosenberger A, Quehenberger F, Krisper N, Prietl B, Reinisch A, Zebisch A, Sill H, Wölfler A.

Cancer Med. 2019 Apr;8(4):1771-1778. doi: 10.1002/cam4.2053. Epub 2019 Mar 7.

7.

Clinical implications of subclonal TP53 mutations in acute myeloid leukemia.

Prochazka KT, Pregartner G, Rücker FG, Heitzer E, Pabst G, Wölfler A, Zebisch A, Berghold A, Döhner K, Sill H.

Haematologica. 2019 Mar;104(3):516-523. doi: 10.3324/haematol.2018.205013. Epub 2018 Oct 11.

8.

Feasibility and safety of using an automated decision support system for insulin therapy in the treatment of steroid-induced hyperglycemia in patients with acute graft-versus-host disease: A randomized trial.

Aberer F, Mader JK, Holzgruber J, Trummer C, Schwetz V, Pandis M, Pferschy PN, Greinix H, Tripolt NJ, Pieber TR, Zebisch A, Sill H, Wölfler A, Sourij H.

J Diabetes Investig. 2019 Mar;10(2):339-342. doi: 10.1111/jdi.12919. Epub 2018 Oct 1.

9.

Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia.

Huemer F, Weiss L, Faber V, Neureiter D, Egle A, Geissler K, Voskova D, Zebisch A, Burgstaller S, Pichler A, Stauder R, Sperr W, Lang A, Pfeilstöcker M, Machherndl-Spandl S, Stampfl M, Greil R, Pleyer L.

Wien Klin Wochenschr. 2018 Feb;130(3-4):115-125. doi: 10.1007/s00508-018-1315-2. Epub 2018 Jan 30.

10.

Loss of RKIP is a frequent event in myeloid sarcoma and promotes leukemic tissue infiltration.

Caraffini V, Perfler B, Berg JL, Uhl B, Schauer S, Kashofer K, Ghaffari-Tabrizi-Wizsy N, Strobl H, Wölfler A, Hoefler G, Sill H, Zebisch A.

Blood. 2018 Feb 15;131(7):826-830. doi: 10.1182/blood-2017-09-804906. Epub 2018 Jan 2. No abstract available.

11.

Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia.

Gaksch L, Kashofer K, Heitzer E, Quehenberger F, Daga S, Hofer S, Halbwedl I, Graf R, Krisper N, Hoefler G, Zebisch A, Sill H, Wölfler A.

Am J Hematol. 2018 Jan;93(1):23-30. doi: 10.1002/ajh.24922. Epub 2017 Oct 19.

12.

Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis.

Magina KN, Pregartner G, Zebisch A, Wölfler A, Neumeister P, Greinix HT, Berghold A, Sill H.

Blood. 2017 Aug 17;130(7):946-948. doi: 10.1182/blood-2017-04-777722. Epub 2017 Jul 5. Review. No abstract available.

PMID:
28679736
13.

Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing.

Kashofer K, Gornicec M, Lind K, Caraffini V, Schauer S, Beham-Schmid C, Wölfler A, Hoefler G, Sill H, Zebisch A.

Leuk Lymphoma. 2018 Feb;59(2):501-504. doi: 10.1080/10428194.2017.1339879. Epub 2017 Jun 20. No abstract available.

14.

Early Hyperglycemia after Initiation of Glucocorticoid Therapy Predicts Adverse Outcome in Patients with Acute Graft-versus-Host Disease.

Stauber MN, Aberer F, Oulhaj A, Mader JK, Zebisch A, Pieber TR, Neumeister P, Greinix HT, Sill H, Sourij H, Wölfler A.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1186-1192. doi: 10.1016/j.bbmt.2017.03.010. Epub 2017 Mar 8.

15.

Hyperglycaemia within the first month after allogeneic haematopoietic stem-cell transplantation is an independent risk factor for overall survival in patients with acute myeloid leukaemia.

Aberer F, Kremser S, Mader JK, Zinke-Cerwenka W, Greinix H, Tripolt NJ, Pieber TR, Zebisch A, Sill H, Oulhaj A, Sourij H, Wölfler A.

Diabetes Metab. 2017 Dec;43(6):560-562. doi: 10.1016/j.diabet.2017.02.001. Epub 2017 Mar 6. No abstract available.

PMID:
28279650
16.

Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia.

Lal R, Lind K, Heitzer E, Ulz P, Aubell K, Kashofer K, Middeke JM, Thiede C, Schulz E, Rosenberger A, Hofer S, Feilhauer B, Rinner B, Svendova V, Schimek MG, Rücker FG, Hoefler G, Döhner K, Zebisch A, Wölfler A, Sill H.

Blood. 2017 May 4;129(18):2587-2591. doi: 10.1182/blood-2016-11-751008. Epub 2017 Mar 3. No abstract available.

PMID:
28258055
17.

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.

Pleyer L, Döhner H, Dombret H, Seymour JF, Schuh AC, Beach CL, Swern AS, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, Thaler J, Halter B, Machherndl Spandl S, Zebisch A, Pichler A, Pfeilstöcker M, Autzinger EM, Lang A, Geissler K, Voskova D, Sperr WR, Hojas S, Rogulj IM, Andel J, Greil R.

Int J Mol Sci. 2017 Feb 15;18(2). pii: E415. doi: 10.3390/ijms18020415.

18.

Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs.

Zebisch A, Hatzl S, Pichler M, Wölfler A, Sill H.

Int J Mol Sci. 2016 Dec 10;17(12). pii: E2080. Review.

19.

Evidence for a role of decitabine in the treatment of myeloid sarcoma.

Gornicec M, Wölfler A, Stanzel S, Sill H, Zebisch A.

Ann Hematol. 2017 Mar;96(3):505-506. doi: 10.1007/s00277-016-2870-0. Epub 2016 Nov 6. No abstract available.

PMID:
27817041
20.

Acute myeloid leukemia with TP53 germ line mutations.

Zebisch A, Lal R, Müller M, Lind K, Kashofer K, Girschikofsky M, Fuchs D, Wölfler A, Geigl JB, Sill H.

Blood. 2016 Nov 3;128(18):2270-2272. Epub 2016 Sep 12. No abstract available.

21.

Autophosphorylation on S614 inhibits the activity and the transforming potential of BRAF.

Dernayka L, Rauch N, Jarboui MA, Zebisch A, Texier Y, Horn N, Romano D, Gloeckner CJ, Kriegsheim Av, Ueffing M, Kolch W, Boldt K.

Cell Signal. 2016 Sep;28(9):1432-9. doi: 10.1016/j.cellsig.2016.06.016. Epub 2016 Jun 21.

22.

Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP.

Hatzl S, Geiger O, Kuepper MK, Caraffini V, Seime T, Furlan T, Nussbaumer E, Wieser R, Pichler M, Scheideler M, Nowek K, Jongen-Lavrencic M, Quehenberger F, Wölfler A, Troppmair J, Sill H, Zebisch A.

Cancer Res. 2016 Jun 15;76(12):3644-54. doi: 10.1158/0008-5472.CAN-15-3049. Epub 2016 Apr 15.

23.

Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.

Pleyer L, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, Thaler J, Halter B, Machherndl-Spandl S, Zebisch A, Pichler A, Pfeilstöcker M, Autzinger EM, Lang A, Geissler K, Voskova D, Geissler D, Sperr WR, Hojas S, Rogulj IM, Andel J, Greil R.

J Hematol Oncol. 2016 Apr 16;9:39. doi: 10.1186/s13045-016-0263-4.

24.

Pulmonary arterial pressure in patients with myelodysplastic syndromes.

Sill H, Kqiku-Kryeziu X, Avian A, Kovacs G, Gaal S, Zebisch A, Olschewski H.

Leuk Lymphoma. 2016 Nov;57(11):2723-6. doi: 10.3109/10428194.2016.1160086. Epub 2016 Apr 15. No abstract available.

PMID:
27082148
25.

Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: Risk factors and efficacy of antibiotic prophylaxis.

Bainschab A, Quehenberger F, Greinix HT, Krause R, Wölfler A, Sill H, Zebisch A.

Leuk Res. 2016 Mar;42:47-51. doi: 10.1016/j.leukres.2016.01.014. Epub 2016 Feb 1.

PMID:
26866663
26.

Deletion of SPRY4 is a frequent event in secondary acute myeloid leukemia.

Geiger O, Hatzl S, Kashofer K, Hoefler G, Wölfler A, Sill H, Zebisch A.

Ann Hematol. 2015 Nov;94(11):1923-4. doi: 10.1007/s00277-015-2445-5. Epub 2015 Jul 25. No abstract available.

27.

Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation.

Milewska M, Romano D, Herrero A, Guerriero ML, Birtwistle M, Quehenberger F, Hatzl S, Kholodenko BN, Segatto O, Kolch W, Zebisch A.

PLoS One. 2015 Jun 12;10(6):e0129859. doi: 10.1371/journal.pone.0129859. eCollection 2015.

28.

Identification of a novel variant of epsilon-gamma-delta-beta thalassemia highlights limitations of next generation sequencing.

Zebisch A, Schulz E, Grosso M, Lombardo B, Acierno G, Sill H, Iolascon A.

Am J Hematol. 2015 Mar;90(3):E52-4. doi: 10.1002/ajh.23913. Epub 2015 Jan 16. No abstract available.

29.

Germline variants in the SEMA4A gene predispose to familial colorectal cancer type X.

Schulz E, Klampfl P, Holzapfel S, Janecke AR, Ulz P, Renner W, Kashofer K, Nojima S, Leitner A, Zebisch A, Wölfler A, Hofer S, Gerger A, Lax S, Beham-Schmid C, Steinke V, Heitzer E, Geigl JB, Windpassinger C, Hoefler G, Speicher MR, Boland CR, Kumanogoh A, Sill H.

Nat Commun. 2014 Oct 13;5:5191. doi: 10.1038/ncomms6191.

30.

Effect of different head-neck positions on physical and psychological stress parameters in the ridden horse.

Zebisch A, May A, Reese S, Gehlen H.

J Anim Physiol Anim Nutr (Berl). 2014 Oct;98(5):901-7. doi: 10.1111/jpn.12155. Epub 2013 Dec 13.

PMID:
24329719
31.

Effects of different head-neck positions on the larynges of ridden horses.

Zebisch A, May A, Reese S, Gehlen H.

J Anim Physiol Anim Nutr (Berl). 2014 Oct;98(5):894-900. doi: 10.1111/jpn.12154. Epub 2013 Dec 13.

PMID:
24329611
32.

Primary antiphospholipid antibody syndrome-one further aspect of thrombophilia in overweight and obese patients with venous thromboembolism.

Gary T, Belaj K, Bruckenberger R, Hackl G, Hafner F, Froehlich H, Zebisch A, Pilger E, Brodmann M.

Obesity (Silver Spring). 2013 Sep;21(9):E463-6. doi: 10.1002/oby.20188. Epub 2013 May 13.

33.

Mutant DNMT3A in acute myeloid leukemia: guilty of inducing genetic instability?

Zebisch A, Hoefler G, Quehenberger F, Wölfler A, Sill H.

Leukemia. 2013 Aug;27(8):1777-8. doi: 10.1038/leu.2013.48. Epub 2013 Feb 18. No abstract available.

PMID:
23417030
34.

Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie.

Troch M, Kiesewetter B, Willenbacher W, Willenbacher E, Zebisch A, Linkesch W, Fridrik M, Müllauer L, Greil R, Raderer M.

Haematologica. 2013 Feb;98(2):264-8. doi: 10.3324/haematol.2012.072587. Epub 2012 Sep 14.

35.

Mutations inDNMT3A and loss of RKIP are independent events in acute monocytic leukemia.

Fried I, Wölfler A, Quehenberger F, Hoefler G, Sill H, Zebisch A.

Haematologica. 2012 Dec;97(12):1936-7. doi: 10.3324/haematol.2012.068429. Epub 2012 Aug 8. No abstract available.

36.

Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms.

Schulz E, Valentin A, Ulz P, Beham-Schmid C, Lind K, Rupp V, Lackner H, Wölfler A, Zebisch A, Olipitz W, Geigl J, Berghold A, Speicher MR, Sill H.

J Med Genet. 2012 Jul;49(7):422-8. doi: 10.1136/jmedgenet-2011-100674. Epub 2012 May 31.

PMID:
22652532
37.

Frequent loss of RAF kinase inhibitor protein expression in acute myeloid leukemia.

Zebisch A, Wölfler A, Fried I, Wolf O, Lind K, Bodner C, Haller M, Drasche A, Pirkebner D, Matallanas D, Rath O, Blyth K, Delwel R, Taskesen E, Quehenberger F, Kolch W, Troppmair J, Sill H.

Leukemia. 2012 Aug;26(8):1842-9. doi: 10.1038/leu.2012.61. Epub 2012 Mar 5.

PMID:
22388727
38.

Raf family kinases: old dogs have learned new tricks.

Matallanas D, Birtwistle M, Romano D, Zebisch A, Rauch J, von Kriegsheim A, Kolch W.

Genes Cancer. 2011 Mar;2(3):232-60. doi: 10.1177/1947601911407323.

39.

Therapy-related myeloid neoplasms: pathobiology and clinical characteristics.

Sill H, Olipitz W, Zebisch A, Schulz E, Wölfler A.

Br J Pharmacol. 2011 Feb;162(4):792-805. doi: 10.1111/j.1476-5381.2010.01100.x. Review.

40.

Functional roles of multiple feedback loops in extracellular signal-regulated kinase and Wnt signaling pathways that regulate epithelial-mesenchymal transition.

Shin SY, Rath O, Zebisch A, Choo SM, Kolch W, Cho KH.

Cancer Res. 2010 Sep 1;70(17):6715-24. doi: 10.1158/0008-5472.CAN-10-1377. Epub 2010 Aug 24.

41.

Gram stain/aolc screening for detection of catheter related bloodstream infection.

Zach J, Zollner-Schwetz I, Krause R, Zebisch A, Rohn A, Sill H.

J Infect. 2010 Mar;60(3):254-5. doi: 10.1016/j.jinf.2010.01.001. Epub 2010 Jan 11. No abstract available.

PMID:
20064554
42.

Loss of RAF kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with C-RAF germline mutations.

Zebisch A, Haller M, Hiden K, Goebel T, Hoefler G, Troppmair J, Sill H.

Leukemia. 2009 Jun;23(6):1049-53. doi: 10.1038/leu.2009.68. Epub 2009 Apr 9.

PMID:
19357705
43.

Enhanced thrombin generation in plasma of severe thrombocytopenic patients due to rFVIIa.

Novak M, Hiden M, Rehak T, Rosenkranz A, Zebisch A, Sill H, Klaschka S, Muntean W.

Hamostaseologie. 2008 Oct;28 Suppl 1:S77-80.

PMID:
18958344
44.

Severe hemolysis as presenting sign of acute erythroleukemia.

Zebisch A, Sill H.

J Clin Oncol. 2008 Jan 10;26(2):330-1. doi: 10.1200/JCO.2007.14.1481. No abstract available.

PMID:
18182675
45.

Are mouthwashes a reliable source of constitutional DNA in patients with leukemia?

Zebisch A, Sill H.

Leuk Res. 2008 Jul;32(7):1164-5. Epub 2007 Dec 21. No abstract available.

PMID:
18082258
46.

Signaling through RAS-RAF-MEK-ERK: from basics to bedside.

Zebisch A, Czernilofsky AP, Keri G, Smigelskaite J, Sill H, Troppmair J.

Curr Med Chem. 2007;14(5):601-23. Review.

PMID:
17346150
47.

Back to the roots: the remarkable RAF oncogene story.

Zebisch A, Troppmair J.

Cell Mol Life Sci. 2006 Jun;63(11):1314-30. Review.

PMID:
16649144
48.

Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia.

Zebisch A, Staber PB, Delavar A, Bodner C, Hiden K, Fischereder K, Janakiraman M, Linkesch W, Auner HW, Emberger W, Windpassinger C, Schimek MG, Hoefler G, Troppmair J, Sill H.

Cancer Res. 2006 Apr 1;66(7):3401-8.

49.

Bedside RNA stabilizing kit systems for gene expression analysis of acute leukemias: influence of non-neoplastic white blood cells.

Zebisch A, Linkesch W, Sill H.

Leukemia. 2005 Apr;19(4):685. No abstract available.

PMID:
15861178
50.

Supplemental Content

Loading ...
Support Center